glp 1 agonists microdose Microdosing GLP-1 Drugs: What To Know Microdosing GLP-1s: Risks & Considerations

5c) (Table 4)

In Phase 1 and 2a clinical trials, once-daily subcutaneous injections of RG7697 (0.252.5 mg) for 14 days in 56 patients with T2DM and 1.8 mg of RG7697 for 12 weeks in patients with T2DM who were poorly responsive to metformin reduced body weight and improved glycemic control

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

It should be noted that physiologic GLP-1R agonism in the periphery mediates food intake reduction via vagal afferent signaling as rats with a surgical subdiaphragmatic vagal deafferentation (SDA) exhibit a more mild food intake suppression in response to acute administration of GLP-1 analogues than sham operated animals (80, 81)

Alzheimers disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links

This includes companies that provide diabetes related medical devices as well as orthopedic devices (total knee replacements are much more common in obese patients)